secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001628280-24-020827
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharma reports Q1 net loss of $51.8M; XOLREMDI approved for WHIM syndrome
----------------------------------------------------------------------------

- Net loss $51.8M vs $24.0M in Q1 2023; includes $13.8M non-cash loss on warrant liability.
- Cash, equivalents, and securities $81.6M as of Mar 31, 2024; runway into 2025 excluding PRV monetization.
- FDA approved XOLREMDI (mavorixafor) for WHIM syndrome in patients 12+ in late April 2024; U.S. launch underway.
- Phase 2 interim data for mavorixafor in chronic neutropenia expected June 2024; Phase 3 trial planned in Q2 2024.
- SG&A expenses rose to $17.4M from $7.2M due to commercial launch preparations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828024020827/0001628280-24-020827-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828024020827/xfor-20240507.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-020827

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer